APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
1 Year Est. Return
+195%
AUM
$936M
AUM Growth
+$589M
(+170%)
Holding
67
Top Buys
| 1 | +$122M | |
| 2 | +$37.6M | |
| 3 | +$29.9M | |
| 4 |
JBIO
Jade Biosciences
JBIO
|
+$20.3M |
| 5 |
Enliven Therapeutics
ELVN
|
+$18.3M |
Top Sells
| 1 | +$10.4M | |
| 2 | +$8.35M | |
| 3 | +$7.81M | |
| 4 |
Agilent Technologies
A
|
+$5.65M |
| 5 |
Pfizer
PFE
|
+$5.07M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Consumer Staples | 0.39% |
| 3 | Consumer Discretionary | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Dianthus Therapeutics
DNTH
$5.08B
| $361M | 38.62% |
4,208,368
+2,104,184
|
|
||
|
ORKA
2
Oruka Therapeutics
ORKA
$3.53B
| $89.3M | 9.55% |
1,520,848
+860,424
|
|
||
3
CG Oncology
CGON
$5.49B
| $87.2M | 9.32% |
1,288,948
-183,751
|
|
||
|
JBIO
4
Jade Biosciences
JBIO
$1.04B
| $53.9M | 5.76% |
2,801,416
+1,400,708
|
|
||
5
Perspective Therapeutics
CATX
$449M
| $48.8M | 5.22% |
12,099,998
+8,889,265
|
|
||
|
6
Enliven Therapeutics
ELVN
$2.41B
| $32.2M | 3.44% |
800,000
+659,700
|
|
||
7
Context Therapeutics
CNTX
$262M
| $24.9M | 2.66% |
9,996,534
+4,491,679
|
|
||
8
Teva Pharmaceuticals
TEVA
$41.1B
| $20.6M | 2.2% |
650,100
+232,800
|
|
||
9
Repligen
RGEN
$6.99B
| $18.4M | 1.96% |
155,600
+105,300
|
|
||
|
PVLA
10
Palvella Therapeutics
PVLA
$1.7B
| $17.7M | 1.89% |
140,000
+120,700
|
|
||
|
AKTS
11
Aktis Oncology
AKTS
$1.15B
| $17.2M | 1.83% |
+937,132
|
|
||
12
Medtronic
MDT
$94.8B
| $16.8M | 1.79% |
200,000
+92,400
|
|
||
13
Vir Biotechnology
VIR
$1.61B
| $14.8M | 1.59% |
+1,569,300
|
|
||
14
Immunic
IMUX
$204M
| $13.9M | 1.48% |
736,935
+266,994
|
|
||
15
DexCom
DXCM
$28.5B
| $11.6M | 1.24% |
+190,000
|
|
||
16
Encompass Health
EHC
$10.5B
| $8.26M | 0.88% |
84,000
+52,400
|
|
||
17
Boston Scientific
BSX
$71.8B
| $7.22M | 0.77% |
120,000
+5,500
|
|
||
18
Tenax Therapeutics
TENX
$315M
| $6.94M | 0.74% |
+481,868
|
|
||
19
Karyopharm Therapeutics
KPTI
$206M
| $6.44M | 0.69% |
927,482
+792,916
|
|
||
20
Humana
HUM
$36.7B
| $5.91M | 0.63% |
+25,000
|
|
||
21
Phathom Pharmaceuticals
PHAT
$765M
| $5.56M | 0.59% |
498,780
+292,704
|
|
||
22
Gilead Sciences
GILD
$167B
| $5.4M | 0.58% |
+40,000
|
|
||
|
MSLE
23
Satellos Bioscience
MSLE
$152M
| $5.27M | 0.56% |
+775,538
|
|
||
|
TEM
24
Tempus AI
TEM
$9.06B
| $4.74M | 0.51% |
+90,000
|
|
||
25
SCYNEXIS
SCYX
$7M
| $3.84M | 0.41% |
4,163,320
+2,081,660
|
|